Manufacturing Capacity DiscGenics operates an in house scalable allogeneic cell manufacturing process and cGMP facility at its Salt Lake City headquarters, enabling control over compliance, cost, and production timelines and creating potential contract manufacturing or co development opportunities for other cell therapies.

Market Potential The lead candidate IDCT targets mild to moderate degenerative disc disease with a large addressable patient population, creating sales opportunities through spine surgeons, pain management clinics, orthopedic centers, and hospital networks seeking regenerative, off the shelf therapies; partnerships with distributors could accelerate adoption.

Funding and Growth DiscGenics has a track record of strong funding and facility expansion, including a Series C financing and multi year expansion in Salt Lake City, signaling capital readiness to scale clinical development, commercialization, and collaborations with manufacturing partners.

Partnerships and Ecosystem Existing collaborations with Gelifesciences, CCRM, and GE Healthcare demonstrate openness to ecosystem partnerships for manufacturing optimization, scale up, regulatory alignment, and supply chain advantages, supporting joint development, licensing, or contract manufacturing discussions.

Domestic Footprint With headquarters in Utah and ongoing expansions in Salt Lake City, DiscGenics offers a US based hub for clinical studies, provider engagement, and payer conversations, enabling targeted outreach to regional spine centers and academic medical centers.